Tipapkinogene sovacivec

Drug Profile

Tipapkinogene sovacivec

Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Transgene
  • Developer European Organisation for Research and Treatment of Cancer; Roche; Transgene
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cancer
  • Discontinued Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer

Most Recent Events

  • 20 Mar 2017 Transgene, in collaboration with Merck and Pfizer, plans a phase II trial for HPV-positive Head and neck cancer in France in the second half of 2017
  • 11 Oct 2016 Transgene, Merck and Pfizer agree to co-develop TG4001 in France for Head and neck cancer
  • 05 Sep 2016 Transgene re-plans a phase II trial for Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top